China National Accord Medicines Corporation Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guoyao Group Yiyi Pharmaceutical Co., Ltd. (referred to as Guoyao Yiyi) is a comprehensive pharmaceutical listed company under China Pharmaceutical Group Co., Ltd. and Guoyao Holdings Co., Ltd. (A share 000028, B share 200028). It is the only pharmaceutical retail integration platform of Guoyao Group in China, covering the entire industry chain of "drug distribution+pharmaceutical logistics+pharmaceutical retail+industrial investment". Ranked 51st among the top 500 enterprises in Guangdong Province and 24th among the top 100 enterprises in Shenzhen. Undertaking the task of special reserves of central, provincial (Guangdong, Guangxi), and municipal (Guangzhou, Shenzhen, Nanning, etc.) pharmaceutical and equipment commodities, as well as the allocation and supply of emergency and disaster relief drugs required throughout the country. Sinopharm is committed to building an "excellent medical supply chain solution and service provider" in the field of drug distribution, leveraging its integrated and large-scale industrial advantages to form a strong commercial network in the southern region of China. As of now, the company has 47 subsidiaries in major regions such as Guangzhou, Shenzhen, Foshan, Dongguan, and Guangzhou, including Zhanjiang, Meizhou, Huizhou, Zhaoqing, Jiangmen, Shaoguan, Zhongshan, Nanning, and Liuzhou. Among them, it ranks among the top three in the hospital direct sales market competition in 31 prefecture level or above cities, achieving deep penetration in the southern region of China. The company has built a "four in one" tiered logistics distribution network consisting of regional logistics centers, provincial logistics centers, urban distribution centers, and distribution stations, expanding new models of modern logistics operations such as multi warehouse operations, third-party logistics, and cold chain management, providing customers and suppliers with professional, efficient, and fast drug distribution and logistics value-added services. In addition, the company actively promotes business transformation and upgrading, focusing on promoting national retail terminal business, and creating a national retail direct sales commercial platform. Adopting advanced supply chain management methods and modern technology, we comprehensively carry out equipment business, expand 4D business, create SPD core competitiveness, and collaborate with medical institutions to extend supply chain management, achieving cost reduction and efficiency increase. At the end of 2019, the sales revenue from distribution exceeded 40 billion yuan. National Pharmaceuticals is consistently working in the field of pharmaceutical retail, partnering with Wobolian, the world's first world-class pharmaceutical and health care enterprise led by pharmacies, to create a Chinese pharmaceutical and health retail brand "National Pharmaceuticals" that consumers can trust. At present, 27 regional chain companies have been established in 21 provinces, autonomous regions, and municipalities across the country, covering 75 prefecture level cities and having over 5000 retail pharmacies. For the past six years, it has consistently ranked first in China's pharmaceutical retail industry. Relying on a series of professional advantages such as advanced management capability, efficient and fast procurement system, strict quality control, fine store management, intimate professional services for chronic diseases, efficient logistics system, and national ERP platform, the Bureau covers retail diagnosis and treatment stores of traditional Chinese medicine, western medicine, traditional Chinese medicine, western medicine, rehabilitation physiotherapy and various medical related resources, innovatively applies the "Internet plus" technology, and cooperates with local governments to carry out online community health construction, Ensuring the health needs of the people. In 2019, the sales revenue of National University Pharmacy exceeded 12 billion yuan. Sinopharm Tongyi Industrial Investment Strategy mainly shares in the industrial enterprises Sinopharm Zhijun Shenzhen Pharmaceutical Co., Ltd., Sinopharm Zhijun Shenzhen Pingshan Pharmaceutical Co., Ltd., Shenzhen Zhijun Pharmaceutical Trade Co., Ltd., Shenzhen Wanle Pharmaceutical Co., Ltd., covering the R&D, production and sales of anti infection, respiratory system drugs, health care products, traditional Chinese patent medicines and simple preparations and anti-tumor drugs. In 2019, the sales revenue of the industrial investment sector exceeded 4 billion yuan. In the future, Sinopharm will continue to adhere to the concept of "caring for life and health", based on the development opportunities of China's pharmaceutical and health industry, transform and innovate, specialize in development, deeply leverage the synergistic effect of distribution and retail resources, promote the strategy of integrating wholesale and retail, and internationalization, promote the digital transformation of the company through scientific and technological innovation, and move towards a leading international pharmaceutical and health service platform and higher scale goals!. |
| Headquarter | Shenzhen |
| Establish Date | 8/2/1986 |
| Listed Code | 000028.SZ |
| Listed Date | 8/9/1993 |
| Chairman | Lin Min. |
| CEO | Lin Zhaoxiong. |
| Website | www.szaccord.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
